1. Saito M, Nanjo M, Kataoka M, Moriya Y, Sugawara Y, Yoshida T, Ishida N. Adoptive immunotherapy by pantropic killer cells recovered from OK-432-injected tumor site in mice. Cancer Res 1988; 48: 4163–4167.
2. Kan N, Okino T, Nakanish M, Sato K, Misu K, Yamasaki S, Teramura Y, Ohgaki K, Tobe T. Therapeutic efficacy of sequential therapy with OK-432, cyclophosphamide, IL-2-cultured lymphocytes andin vivo IL-2 against advanced murine plasmacytoma. Biotherapy 1989; 1: 197–206.
3. Sekimoto M, Kokunai I, Shimano T, Kobayashi T, Takeda T, Haruna N, Yamamoto A, Mori T. Production of tumor necrosis factor (TNF) by monocytes from cancer patients and healthy subjects induced by OK-432in vitro, and its augmentation by interferon gamma. J Clin Lab Immunol 1988; 27: 115–120.
4. Haruna N, Monden T, Morimoto H, Murotani M, Yagyu T, Nagaoka H, Shimano T, Mori T. Use of a rapid microwave fixation technique for immunocytochemical demonstration of tumor necrosis factor, interleukin-1, and interleukin-1 in activated human peripheral mononuclear cells. Acta Histochem Cytochem 1990; 23: 563–572.
5. Torisu M, Katano M, Kimura Y, Itou H, Takesue M. New approach to management of malignant ascites with a Streptococcal preparation, OK-432. I. Improvement of host immunity and prolongation of survival. Surgery 1983; 93: 357–364.